Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)

Editor’s Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc. (NASDAQ:AMGN), Acorda Therapeutics Inc (NASDAQ:ACOR), Myriad Genetics, Inc. (NASDAQ:MYGN)

Theravance Rises on FDA Staff Report on Lung Drug With Glaxo (Bloomberg)
Theravance Inc (NASDAQ:THRX) rose the most in a year after a staff report by U.S. regulators showed the once- daily lung disease treatment the company is developing with GlaxoSmithKline Plc (GSK) may be able to win approval. Theravance rose 20 percent to $28.62 at 10:15 a.m. New York time after reaching $29.11 for its biggest intraday gain since April 2012. The medication called Breo is meant to treat chronic obstructive pulmonary disease, an umbrella term for emphysema and chronic bronchitis.

VIVUS, Inc. (NASDAQ:VVUS) to make changes in its Risk Evaluation strategy (US Market Buzz)
VIVUS, Inc. (NASDAQ:VVUS)’s intention to revise the risk management plan for its anti-obesity drug Qsymia would not guarantee its success, a top shareholder of the company said. Qsymia, one of the two weight loss drugs approved by the US Food and Drug Administration, has not seen selling as successfully as expected.

Theravance Inc (NASDAQ:THRX)Amgen Stock Rating Reaffirmed by Barclays Capital (AMGN) (Daily Political)
Amgen, Inc. (NASDAQ:AMGN)‘s stock had its “equal weight” rating reiterated by equities research analysts at Barclays Capital in a research note issued to investors on Monday, Analyst Ratings.Net reports. They currently have a $105.00 price target on the stock. A number of other analysts have also recently weighed in on AMGN. Analysts at UBS AG raised their price target on shares of Amgen from $98.00 to $121.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Lazard Capital Markets raised their price target on shares of Amgen, Inc. (NASDAQ:AMGN) from $106.00 to $125.00 in a research note to investors on Thursday.

Acorda Therapeutics rises on Ampyra study (San Francisco Chronicle)
Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) jumped Monday after the company said that its drug Ampyra helped stroke patients recover their ability to walk in a mid-stage clinical trial. Acorda said patients who took Ampyra recovered were able to walk faster and had an easier time performing daily tasks. The trial involved 83 patients who had an ischemic stroke at least six months earlier, and who still had walking problems. Ischemic strokes occur when a blood vessel that supplies blood to the brain is blocked.

Myriad Genetics CEO Claims He Owns Your Genes (Forbes)
Today, in a letter filled with non sequiturs and distortions, Myriad Genetics, Inc. (NASDAQ:MYGN)’s CEO Peter Meldrum, worried about whether his company will be able to maintain their monopoly on a test for which they charge $4000, responded. Let’s look at his claims. First, though, let me remind readers that the genes in question, BRCA1 and BRCA2, are linked to an increased risk of breast and ovarian cancer, a risk that was first discovered in 1994 by scientists at the University of Utah.

Theravance Inc (THRX): Here’s One Thing To Know About The Stock Today (Insider Monkey)
Theravance Inc (NASDAQ:THRX) has experienced a decrease in support from the world’s most elite money managers of late, but insiders on the whole appear bullish. More importantly, shares of Theravance are up more than…

…18% today on the hope of a fruitful FDA decision later this week. With that in mind, it’s important to look at how hedge funds and insiders have been trading it of late.

Stocks Review: VIVUS, Inc.(NASDAQ:VVUS), Amgen, Inc. (NASDAQ:AMGN), Lincoln National Corporation(NYSE:LNC) (Meshpress)
VIVUS, Inc. (NASDAQ:VVUS)VIVUS, Inc. (NASDAQ:VVUS) shares climbed 3.88% to $11.25. First Manhattan Co. (FMC), an owner-operated investment advisory firm and the beneficial holder of approximately 9.1 percent of the outstanding shares of VIVUS, Inc. (“Vivus”), on April 10 issued a statement in anticipation of the expected announcement from VIVUS, Inc. (NASDAQ:VVUS) that its obesity treatment Qsymia has received a modification in its Risk Evaluation and Mitigation Strategy (REMS). Additionally, the company, on March 26, announced that it has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors.

April 27: Mayor’s Ride to Kick Off Amgen Bike Tour (SCVNews.com)
Santa Clarita community members are invited to join Mayor Bob Kellar for a free community bike ride beginning at 8:30 a.m. on Saturday, April 27, at the Iron Horse Trailhead located off of Magic Mountain Parkway near Tourney Road. The Mayor’s Ride will kick off a series of events surrounding the 2013 Amgen, Inc. (NASDAQ:AMGN) Tour of California professional cycling race, which is set to ride through Santa Clarita on Tuesday, May 14 and Wednesday, May 15, 2013. The Mayor’s Ride is a family friendly event where riders of any level can participate.

Acorda Therapeutics Price Target Raised to $40.00 at Aegis (ACOR) (Zolmax)
Equities researchers at Aegis boosted their target price on shares of Acorda Therapeutics Inc (NASDAQ:ACOR) from $34.00 to $40.00 in a report issued on Monday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Shares of Acorda Therapeutics (NASDAQ: ACOR) traded up 9.20% during mid-day trading on Monday, hitting $34.42. Acorda Therapeutics has a one year low of $21.04 and a one year high of $32.92. The stock’s 50-day moving average is currently $30.73. The company has a market cap of $1.386 billion and a P/E ratio of 8.21.

Myriad Genetics (NASDAQ: MYGN) Could Get Crushed (Wealth Daily)
This week the Supreme Court will provide an oral hearing to decide whether or not the gene patents should be allowed. This is based on a challenge of Myriad Genetics, Inc. (NASDAQ:MYGN), which currently holds patents on a variety of genes linked primarily to ovarian and breast cancer. The Supreme Court will hear a host of arguments in the coming week, including those from doctors, cancer survivors, patients, and scientists, all of whom feel as if genes should not be allowed to be patented by corporations. A decision in the case is expected to be completed by June 2013.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!